247 related articles for article (PubMed ID: 34030918)
21. Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment.
Qu LT; Peters S; Cobb AN; Godellas CV; Perez CB; Vaince FT
Am J Surg; 2018 Mar; 215(3):530-533. PubMed ID: 29246403
[TBL] [Abstract][Full Text] [Related]
22. Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy.
Murphy BM; Hoskin TL; Degnim AC; Boughey JC; Hieken TJ
Ann Surg Oncol; 2021 Dec; 28(13):8729-8739. PubMed ID: 34275042
[TBL] [Abstract][Full Text] [Related]
23. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer.
Ladak F; Chua N; Lesniak D; Ghosh S; Wiebe E; Yakimetz W; Rajaee N; Olson D; Peiris L
Can J Surg; 2022; 65(1):E89-E96. PubMed ID: 35135785
[TBL] [Abstract][Full Text] [Related]
24. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
[TBL] [Abstract][Full Text] [Related]
25. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
[TBL] [Abstract][Full Text] [Related]
26. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.
Kim JY; Park HS; Kim S; Ryu J; Park S; Kim SI
Medicine (Baltimore); 2015 Oct; 94(43):e1720. PubMed ID: 26512562
[TBL] [Abstract][Full Text] [Related]
28. Nodal positivity in patients with clinically and radiologically node-negative breast cancer treated with neoadjuvant chemotherapy: multicentre collaborative study.
Zaborowski AM; Doogan K; Clifford S; Dowling G; Kazi F; Delaney K; Yadav H; Brady A; Geraghty J; Evoy D; Rothwell J; McCartan D; Heeney A; Barry M; Walsh SM; Stokes M; Kell MR; Allen M; Power C; Hill ADK; Connolly E; Alazawi D; Boyle T; Corrigan M; O'Leary P; Prichard RS
Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38055888
[TBL] [Abstract][Full Text] [Related]
29. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
Zetterlund LH; Frisell J; Zouzos A; Axelsson R; Hatschek T; de Boniface J; Celebioglu F
Breast Cancer Res Treat; 2017 May; 163(1):103-110. PubMed ID: 28224384
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis.
van Nijnatten TJ; Schipper RJ; Lobbes MB; Nelemans PJ; Beets-Tan RG; Smidt ML
Eur J Surg Oncol; 2015 Oct; 41(10):1278-87. PubMed ID: 26329781
[TBL] [Abstract][Full Text] [Related]
31. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
32. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
[TBL] [Abstract][Full Text] [Related]
33. [The feasibility and the role of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
Péley G; Török K; Farkas E; Mátrai Z; Horváth Z; Sinkovics I; Hitre E; Rényi-Vámos F; Orosz Z; Köves I
Magy Onkol; 2006; 50(1):19-23. PubMed ID: 16617379
[TBL] [Abstract][Full Text] [Related]
34. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
35. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
Eun NL; Son EJ; Gweon HM; Kim JA; Youk JH
Eur Radiol; 2020 Mar; 30(3):1460-1469. PubMed ID: 31802216
[TBL] [Abstract][Full Text] [Related]
36. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
[TBL] [Abstract][Full Text] [Related]
37. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients.
Canavese G; Tinterri C; Carli F; Garrone E; Spinaci S; Della Valle A; Barbieri E; Marrazzo E; Bruzzi P; Dozin B
Eur J Surg Oncol; 2021 Aug; 47(8):1920-1927. PubMed ID: 33972144
[TBL] [Abstract][Full Text] [Related]
38. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
[TBL] [Abstract][Full Text] [Related]
39. [Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer].
Tokita H; Aruga T; Yamashita T; Saji S; Suzuki E; Horiguchi K; Kitagawa D; Sekine S; Horiguchi S; Hirashima Y; Kuroi K
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1639-45. PubMed ID: 21996959
[TBL] [Abstract][Full Text] [Related]
40. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]